Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01762033 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma
A Phase 2 study, sponsored by Lpath.
- Terminated
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT01762033 is a Phase 2 study that was terminated before completion, run by Lpath. The registered enrollment target is 40 participants.
The verdict
NCT01762033, a Phase 2 study, was terminated before completion, sponsored by Lpath.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This Phase 2a study will investigate the efficacy, safety and tolerability of ASONEP™ (sonepcizumab/LT1009) when administered intravenously once a week, every 4 weeks (or cycle), to subjects with refractory renal cell carcinoma (RCC) until the disease progresses. Subjects who have failed 3 prior treatments for RCC including vascular endothelial growth factor (VEGF) and/or mammalian target of rapamycin (mTOR) inhibitors or who have tumors that cannot be surgically removed will be eligible for screening.
Interventions
- DRUG ASONEP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2013-02 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01762033
The ClinicalTrials.gov registry entry for NCT01762033 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lpath, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ASONEP is the first listed.
NCT01762033 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01762033 about?
NCT01762033 is a clinical study titled "A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma". This Phase 2a study will investigate the efficacy, safety and tolerability of ASONEP™ (sonepcizumab/LT1009) when administered intravenously once a week, every 4 weeks (or cycle), to subjects with refractory renal cell carcinoma (RCC) until the disease progresses. Subjects who have failed 3 prior tre...
What is the current status of trial NCT01762033?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2013-02. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01762033?
The interventions under investigation include: ASONEP (DRUG).
Who is sponsoring clinical trial NCT01762033?
This trial is sponsored by Lpath, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.